Merck's Winrevair gains FDA priority review for PAH label update after ZENITH trial shows major reduction in serious events and strong clinical impact.

PAH patients with cardiovascular disease risk had similar hospitalization and mortality rates as those without after a ...

Panelists discuss recent trial data demonstrating that a novel agent not only slows lung function decline but also delays ...

Merck (MRK) stock in focus as its lung disease drug Winrevair gains FDA priority review for a label update based on Phase 3 ...

The Cardiac Centre at Al Qassimi Hospital, operated by Emirates Health Services (EHS), has become the first facility in the ...

Seven cases of patent ductus arteriosus with pulmonary hypertension and reversal of the usual direction of flow are described. Breathing of a low oxygen mixture either initiated or increased the ...